Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its novel multiple sclerosis (MS) therapy, Lucid-MS, toward Phase 2 clinical trials following successful Phase 1 safety and tolerability studies. Unlike conventional MS treatments that primarily target the immune system, Lucid-MS is a patented, first-in-class drug candidate designed to directly protect the myelin sheath damaged by MS. The therapy has demonstrated the ability to prevent and reverse myelin degradation in preclinical studies, supported by more than a decade of scientific research.
The company is also collaborating with researchers at Massachusetts General Hospital to validate a novel PET imaging technique that may enable direct measurement of myelin integrity in MS patients, potentially providing a critical tool for assessing treatment efficacy. This development highlights Quantum BioPharma's focus on neurodegenerative and metabolic disorders, with a pipeline that includes drug candidates for alcohol misuse disorders as well.
The editorial featuring Quantum BioPharma also covered advancements across the neurological and immune-mediated disease sectors, including programs from Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB), and Clene Inc. (NASDAQ: CLNN). For more details, the full press release is available at https://ibn.fm/iZmx1.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Additionally, Quantum invented UNBUZZD(TM) and retains a 19.84% ownership stake as of March 31, 2026, along with royalty payments from sales.
For the latest news and updates regarding QNTM, visit the company’s newsroom at https://ibn.fm/QNTM.
